Anteraper, Sheeba Arnold
Guell, Xavier
Lee, Yoon Ji
Raya, Jovicarole
Demchenko, Ilya
Churchill, Nathan W.
Frey, Benicio N.
Hassel, Stefanie
Lam, Raymond W.
MacQueen, Glenda M.
Milev, Roumen
Schweizer, Tom A.
Strother, Stephen C.
Whitfield-Gabrieli, Susan
Kennedy, Sidney H.
Bhat, Venkat http://orcid.org/0000-0002-8768-1173
,
Funding for this research was provided by:
ontario brain institute
Article History
Accepted: 29 November 2021
First Online: 13 January 2022
Declarations
:
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All study procedures were approved by the Institutional Ethics Board at University Health Network, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Ontario, Canada; St. Joseph’s Healthcare, Hamilton, Ontario, Canada; Providence Care Hospital, Kingston, Ontario, Canada; Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada; and Hotchkiss Brain Institute, Calgary, Alberta, Canada.
: All participants provided written, informed consent to participate in the study and have their data published.
: <b>SAA, XG, YJL, JR, ID, NWC, BNF, SH, GMM, TAS,</b> and <b>SWG</b> have no conflicts of interest to declare. <b>RWL</b> has received honoraria or research funds from Allergan, Asia–Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Hansoh, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Mitacs, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and VGH-UBC Hospital Foundation. <b>RM</b> has received consulting and speaking honoraria from AbbVie, Allergan, Eisai, Janssen, KYE, Lallemand, Lundbeck, Otsuka, and Sunovion, and research grants from CAN-BIND, Canadian Institutes of Health Research, Janssen, Lallemand, Lundbeck, Nubiyota, Ontario Brain Institute, and Ontario Mental Health Foundation. <b>SCS</b> reports partial support from Canadian Biomarker Integration Network in Depression and Canadian Institutes of Health Research (MOP 137097) grants during the conduct of the study, and grants from Ontario Brain Institute, Canadian Foundation for Innovation and Brain Canada, outside the submitted work. He is also a senior scientific advisor for the neuroimaging data analysis company ADMdx, Inc. ( ExternalRef removed), which specializes in brain image analysis to enable diagnosis, prognosis, and drug effect detection for Alzheimer disease and various other forms of dementia. <b>SHK</b> has received honoraria or research funds from Abbott, Alkermes, Allergan, Boehringer Ingelheim, Brain Canada, Canadian Institutes of Health Research, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion, Sun Pharmaceuticals, and holds stock in Field Trip Health. <b>VB</b> is supported by an Academic Scholar Award from the University of Toronto Department of Psychiatry, and has received research support from Canadian Institutes of Health Research, Brain & Behavior Foundation, Ministry of Health Innovation Funds, Royal College of Physicians and Surgeons of Canada, Department of Defense, Canada, New Frontiers in Research Fund, and an investigator-initiated trial from Roche Canada.